Skip to main content
Signal8
Launch Terminal

Opthea Ltd (CKDXF)

Ceryvyn Therapeutics Ltd is a clinical-stage biopharmaceutical company developing therapies for the rare lung disease lymphangioleiomyomatosis (LAM). Its lead program, CYV-101, is a fusion protein designed to neutralize VEGF-C and VEGF-D, key signaling proteins involved in the disease. The company was formerly known as Opthea Limited.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Ceryvyn Therapeutics Ltd logo

Ceryvyn Therapeutics Ltd

OTC:CKDXFHealthcare
Mkt Cap-
Float1.17B
O/S-
Inst Own-
SI0.3%
Dilution
Ceryvyn Therapeutics Ltd logoOTC:CKDXF
FormDescription
13G/A
Beneficial Ownership Report (Amended)
15F-12B
SEC Filing
6-K
Foreign Private Issuer Report
6-K
Foreign Private Issuer Report
S-8 POS
SEC Filing
25
SEC Filing
6-K
Foreign Private Issuer Report
6-K
Foreign Private Issuer Report
6-K
Foreign Private Issuer Report
6-K
Foreign Private Issuer Report
6-K
Foreign Private Issuer Report
20-F
Foreign Annual Report
6-K
Foreign Private Issuer Report
6-K
Foreign Private Issuer Report
6-K
Foreign Private Issuer Report
6-K
Foreign Private Issuer Report
6-K
Foreign Private Issuer Report
6-K
Foreign Private Issuer Report
6-K
Foreign Private Issuer Report
6-K
Foreign Private Issuer Report
6-K
Foreign Private Issuer Report
6-K
Foreign Private Issuer Report
6-K
Foreign Private Issuer Report
6-K
Foreign Private Issuer Report
6-K
Foreign Private Issuer Report

1-25 of 204

…